Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: Effect of bevacizumab/paclitaxel combination therapy

Magnetic Resonance Materials in Physics, Biology and Medicine

Volumn 27, Issue 2, 2014, Pages 161-170

  Zhu, Wenlian ^a   Kato, Yoshinori ^a   Artemov, Dmitri ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination antiangiogenic therapy; DCE MRI; Tumor vascular volume and vascular permeability; Water exchange

Indexed keywords

MUS;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL;

ALGORITHM; ANIMAL; ARTICLE; ARTIFACT; BODY WATER; COMPUTER ASSISTED DIAGNOSIS; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMAGE ENHANCEMENT; MCF 7 CELL LINE; METABOLISM; METHODOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REPRODUCIBILITY; SCID MOUSE; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ARTIFACTS; BODY WATER; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MCF-7 CELLS; MICE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84898059203     PISSN: 09685243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10334-013-0389-0     Document Type: Article

References (42)

1. O'Connor JP, Jackson A, Parker GJ, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 96:189-195
2. Preda A, Novikov V, Moglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP (2004) MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Reson Imaging 20:865-873
3. Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24:3293-3298
4. Heilmann M, Kiessling F, Enderlin M, Schad LR (2006) Determination of pharmacokinetic parameters in DCE MRI: consequence of nonlinearity between contrast agent concentration and signal intensity. Invest Radiol 41:536-543
5. Schabel MC, Parker DL (2008) Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol 53:2345-2373
6. Buckley DL, Parker GJ (2005) Measuring contrast agent concentration in T1-weighted dynamic contrast-enhanced MRI. In: Jackson A, Buckley DL, Parker GJ (eds) Dynamic contrast-enhanced magnetic resonance imaging in oncology, diagnostic imaging. Springer, Berlin, pp 69-79
7. Donahue KM, Weisskoff RM, Chesler DA, Kwong KK, Bogdanov AA Jr, Mandeville JB, Rosen BR (1996) Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 36:858-867
8. Li X, Huang W, Rooney WD (2012) Signal-to-noise ratio, contrast-to-noise ratio and pharmacokinetic modeling considerations in dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 30:1313-1322
9. Burstein HJ (2011) Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol 29:1232-1235
10. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293
11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
12. Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, Yu HJ, Nalcioglu O, Su MY (2009) Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 16:1619-1628
13. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M (2001) Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3:143-153
14. Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, Fujimoto-Ouchi K (2010) Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 21:687-694
15. Oku N, Doi K, Namba Y, Okada S (1994) Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int J Cancer 58:415-419
16. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, Brasch RC (1987) Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 22:665-671
17. Kato Y, Okollie B, Raman V, Vesuna F, Zhao M, Baker SD, Bhujwalla ZM, Artemov D (2007) Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther 6:891-897
18. Levitt MH (1982) Symmetrical composite pulses for NMR population inversion. I. Compensation of radiofrequency field inhomogeneity. J Magn Reson 48:234-264
19. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PE (2003) Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9:355-362
20. Donahue KM, Burstein D, Manning WJ, Gray ML (1994) Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med 32:66-76
21. Vexler VS, Clement O, Schmitt-Willich H, Brasch RC (1994) Effect of varying the molecular weight of the MR contrast agent Gd-DTPA-polylysine on blood pharmacokinetics and enhancement patterns. J Magn Reson Imaging 4:381-388
22. Blasberg RG, Fenstermacher JD, Patlak CS (1983) Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J Cereb Blood Flow Metab 3:8-32
23. Chen H, Li F, Zhao X, Yuan C, Rutt B, Kerwin WS (2011) Extended graphical model for analysis of dynamic contrast-enhanced MRI. Magn Reson Med 66:868-878
24. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
25. Shames DM, Kuwatsuru R, Vexler V, Muhler A, Brasch RC (1993) Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: a quantitative noninvasive technique. Magn Reson Med 29:616-622
26. Roberts HC, Roberts TP, Brasch RC, Dillon WP (2000) Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 21:891-899
27. Windberger U, Bartholovitsch A, Plasenzotti R, Korak KJ, Heinze G (2003) Whole blood viscosity, plasma viscosity and erythrocyte aggregation in nine mammalian species: reference values and comparison of data. Exp Physiol 88:431-440
28. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392
29. Bogin L, Degani H (2002) Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res 62:1948-1951
30. Wall A, Persigehl T, Hauff P, Licha K, Schirner M, Muller S, von Wallbrunn A, Matuszewski L, Heindel W, Bremer C (2008) Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG). Breast Cancer Res BCR 10:R23
31. Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwalla ZM (2005) Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res 65:1425-1432
32. Cheng HL, Wright GA (2006) Rapid high-resolution T(1) mapping by variable flip angles: accurate and precise measurements in the presence of radiofrequency field inhomogeneity. Magn Reson Med 55:566-574
33. Fournier LS, Novikov V, Lucidi V, Fu Y, Miller T, Floyd E, Shames DM, Brasch RC (2007) MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Radiology 243:105-111
34. Sennino B, Raatschen HJ, Wendland MF, Fu Y, You WK, Shames DM, McDonald DM, Brasch RC (2009) Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice. Magn Reson Med 62:616-625
35. Savai R, Langheinrich AC, Schermuly RT, Pullamsetti SS, Dumitrascu R, Traupe H, Rau WS, Seeger W, Grimminger F, Banat GA (2009) Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 11:48-56
36. Kim E, Cebulla J, Ward BD, Rhie K, Zhang J, Pathak AP (2012) Assessing breast cancer angiogenesis in vivo: which susceptibility contrast MRI biomarkers are relevant. Magn Reson Med
37. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121
38. Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N (2008) Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49:522-527
39. Nagy JA, Dvorak HF (2012) Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Clin Exp Metastasis 29:657-662
40. Goldfarb SB, Traina TA, Dickler MN (2010) Bevacizumab for advanced breast cancer. Womens Health (Lond Engl) 6:17-25
41. Smith IE, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, Gonzalez-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI (2011) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol 22:595-602
42. von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Muller BM, Denkert C, Loibl S, Nekljudova V, Untch M (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299-309